INS and diabetes mellitus: Since human insulin was approved by the FDA (Food and Drug Administration) in 1982, when it became the first commercially available recombinant therapeutic protein [1], several therapeutic proteins and peptides have been endorsed for clinical use and others are under development for the therapy of various diseases such as cancer [2], hepatitis [3], and diabetes [4,5].